Novartis has received approval in Switzerland for Coartem Baby, the first drug designed specifically to treat malaria in ...

Novartis wins Swiss approval for Coartem Baby, first malaria drug for infants and young children Novartis ( NYSE: NVS) on ...

Novartis said on Tuesday it had received approval in Switzerland for Coartem Baby, which it said was the first drug to treat ...

Basel: Novartis has received approval from Swissmedic for Coartem (artemether-lumefantrine) Baby, a first malaria medicine ...

The drug, known as Coartem Baby or Riamet Baby in some countries, has been approved by Swiss authorities for use in babies ...

Novartis Pharma AG, affiliated to Swiss drug major Novartis AG (NVS), announced Tuesday that Coartem (artemether-lumefantrine) Baby has been approved by Swissmedic as the first malaria medicine for ...

The newly approved medication, Coartem Baby, is a combination of two antimalarials. It is a lower dose version of a tablet ...

Coartem Baby, which was cleared by health authorities in Switzerland, will fill an important gap in treatment. Novartis plans ...

Novartis' Coartem Baby wins Swiss approval as the first malaria drug for newborns under 5 kg, offering safer dosing and easier administration.

Novartis and a Swiss nonprofit have made history, scoring the world’s first approval for a medicine to treat babies who are ...

Swissmedic approves Novartis’ Coartem Baby to treat malaria in newborns and young infants: Basel Thursday, July 10, 2025, 11:00 Hrs [IST] Novartis announced Coartem (artemether- ...

The medicine, called Coartem Baby (also known as Riamet Baby), was approved by Switzerland’s health agency, Swissmedic.